SG11201805942UA - Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone - Google Patents

Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Info

Publication number
SG11201805942UA
SG11201805942UA SG11201805942UA SG11201805942UA SG11201805942UA SG 11201805942U A SG11201805942U A SG 11201805942UA SG 11201805942U A SG11201805942U A SG 11201805942UA SG 11201805942U A SG11201805942U A SG 11201805942UA SG 11201805942U A SG11201805942U A SG 11201805942UA
Authority
SG
Singapore
Prior art keywords
international
ethanone
pct
methods
intravenous administration
Prior art date
Application number
SG11201805942UA
Inventor
Bryan Oronsky
Jan Scicinski
Scott Caroen
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of SG11201805942UA publication Critical patent/SG11201805942UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 01110111011101111011111100 111110 ill OEN International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/123593 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/397 (2006.01) A61K 35/14 (2015.01) A61K 9/08 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/012948 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: 11 January 2017 (11.01.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/277,236 11 January 2016 (11.01.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: EPICENTRX, INC. [US/US]; 800 W. El Camino Real, Suite 180, Mountain View, CA 94040 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, — (72) Inventors: ORONSKY, Bryan, T.; 28540 Matadero Creek Lane, Los Altos Hills, CA 94022 (US). SCICIN- SKI, Jan; 19546 Vineyard Lane, Saratoga, CA 95070 (US). CAROEN, Scott; 680 Mission Street, Apt. 30P, San Francisco, CA 94105 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Agents: DAVIS, Chad, E. et al.; Goodwin Procter LLP, (74) Published: = 100 Northern Avenue, Boston, MA 02210 (US). — with international search report (Art. 21(3)) = = = = = = = = = = = 1-1 M C:7 kin M ei ,-1 IN 1-1 (54) Title: COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROM0-1-(3,3-DINITROAZ- © ETIDIN-1-YL)ETHANONE ei e i. ) (57) : The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin- 1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly admin- istered to a patient by intravenous infusion without any significant pain at the site of infusion.
SG11201805942UA 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone SG11201805942UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277236P 2016-01-11 2016-01-11
PCT/US2017/012948 WO2017123593A1 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Publications (1)

Publication Number Publication Date
SG11201805942UA true SG11201805942UA (en) 2018-08-30

Family

ID=59311661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805942UA SG11201805942UA (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Country Status (15)

Country Link
US (1) US11576895B2 (en)
EP (1) EP3402480B1 (en)
JP (1) JP6931004B2 (en)
KR (1) KR20190040931A (en)
CN (1) CN109069420A (en)
AU (1) AU2017207304B2 (en)
BR (1) BR112018014027A2 (en)
CA (1) CA3011103A1 (en)
DK (1) DK3402480T3 (en)
EA (1) EA201891606A1 (en)
ES (1) ES2880482T3 (en)
MX (1) MX2018008528A (en)
PL (1) PL3402480T3 (en)
SG (1) SG11201805942UA (en)
WO (1) WO2017123593A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
DK3402480T3 (en) 2016-01-11 2021-06-28 Epicentrx Inc COMPOSITIONS AND PROCEDURES FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1- (3,3-DINITROAZETIDIN-1-YL) ETHANONE
CN110352190A (en) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 Sulphur oxygroup alkyl Organic nitro and related compound and pharmaceutical composition for medical application
EP3648740A1 (en) 2017-07-07 2020-05-13 EpicentRx, Inc. Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
KR20220113996A (en) 2019-12-11 2022-08-17 에피센트알엑스, 인코포레이티드 Drug infusion devices, systems and methods
WO2022261284A1 (en) * 2021-06-09 2022-12-15 Epicentrx, Inc. Crystalline abdnaz compositions and methods of making and using the same
WO2023154480A1 (en) * 2022-02-10 2023-08-17 Epicentrx, Inc. Compositions and methods for treatment of nafld and nash and related dyslipidemias
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
JPS4830376B1 (en) 1970-12-29 1973-09-19
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) * 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (en) 1990-11-13 1997-09-30 株式会社日立製作所 Display control device
TW198712B (en) 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ATE168014T1 (en) 1991-11-08 1998-07-15 Somatogen Inc HEMOGLOBINS AS A DRUG DELIVERY SYSTEM
DE4226974C2 (en) 1992-08-14 1994-08-11 Fresenius Ag Method and device for the continuous preparation of a cell suspension
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
ES2092460T3 (en) 1994-05-27 2001-02-01 Cellegy Pharma Inc GIVING COMPOSITION OF NITRIC OXIDE FOR THE TREATMENT OF ANAL DISORDERS.
AU701843B2 (en) 1995-03-14 1999-02-04 Siemens Aktiengesellschaft Removable precision dosating unit for ultrasonic atomizer device
JP3585127B2 (en) 1995-03-14 2004-11-04 シーメンス アクチエンゲゼルシヤフト Ultrasonic spray system
AU5798996A (en) 1995-05-15 1996-11-29 Sachs, Michael C. Adnaz, compositions and processes
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
JP2001506974A (en) 1996-10-11 2001-05-29 ワーナー―ランバート・コンパニー Aspartate ester inhibitor of interleukin-1β converting enzyme
AU3129097A (en) 1996-10-15 1998-05-11 Eastman Chemical Company Explosive formulations
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
YU73902A (en) 2000-04-10 2005-09-19 Pfizer Products Inc. Benzoamide piperidine containing compounds and related compounds
US6861530B2 (en) 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
DE10111049A1 (en) 2001-03-06 2002-09-12 Beiersdorf Ag Cosmetic or dermatological preparations for combating inflammatory disorders or dryness of the skin, containing agents inhibiting the onset of nitrogen monoxide synthase activity
EP1459724B1 (en) 2001-12-28 2013-11-20 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004004648A2 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
US20040167212A1 (en) 2002-10-07 2004-08-26 Bednarski Mark D. X-nitro compounds, pharmaceutical compositions thereof and uses thereof
CA2518506A1 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
RU2326864C2 (en) 2003-06-25 2008-06-20 Дзе Ил Фармасьютикал Ко., Лтд. Tricyclic derivatives or their pharmaceutical salts, method of obtaining them and their pharmaceutical compounds
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
WO2006029385A2 (en) 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US20060264415A1 (en) 2005-04-01 2006-11-23 Methylgene Inc. Inhibitors of histone deacetylase
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
JP2009510073A (en) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト Carboxyamine compounds and methods of use thereof
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US20120149678A1 (en) 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052164A1 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US20140220163A1 (en) 2014-02-04 2014-08-07 Hamzeh Soleimani Babadi Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
DK3402480T3 (en) 2016-01-11 2021-06-28 Epicentrx Inc COMPOSITIONS AND PROCEDURES FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1- (3,3-DINITROAZETIDIN-1-YL) ETHANONE
CN110352190A (en) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 Sulphur oxygroup alkyl Organic nitro and related compound and pharmaceutical composition for medical application
EP3648740A1 (en) 2017-07-07 2020-05-13 EpicentRx, Inc. Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
WO2019164594A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. METHODS AND COMPOSITIONS UTILIZING RRx-001 FOR RADIOPROTECTION

Also Published As

Publication number Publication date
EP3402480A4 (en) 2019-09-18
JP6931004B2 (en) 2021-09-01
AU2017207304A1 (en) 2018-07-26
ES2880482T3 (en) 2021-11-24
MX2018008528A (en) 2019-05-16
US20190307723A1 (en) 2019-10-10
PL3402480T4 (en) 2021-11-22
WO2017123593A1 (en) 2017-07-20
JP2019505585A (en) 2019-02-28
EA201891606A1 (en) 2019-02-28
CA3011103A1 (en) 2017-07-20
CN109069420A (en) 2018-12-21
EP3402480B1 (en) 2021-03-24
DK3402480T3 (en) 2021-06-28
BR112018014027A2 (en) 2018-12-11
PL3402480T3 (en) 2021-11-22
AU2017207304B2 (en) 2022-05-26
US11576895B2 (en) 2023-02-14
EP3402480A1 (en) 2018-11-21
KR20190040931A (en) 2019-04-19

Similar Documents

Publication Publication Date Title
SG11201805942UA (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201900228YA (en) Administration and dosage of diaminophenothiazines
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201808306PA (en) Treatment of cancer with tg02
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805771XA (en) Systems and methods for preparation of platelets